Skip Navigation

JNCI Journal of the National Cancer Institute 2001 93(7):486-488; doi:10.1093/jnci/93.7.486
© 2001 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Veronesi, U.
Right arrow Articles by Decensi, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Veronesi, U.
Right arrow Articles by Decensi, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 93, No. 7, 486-488, April 4, 2001
© 2001 Oxford University Press

EDITORIAL

Retinoids for Ovarian Cancer Prevention: Laboratory Data Set the Stage for Thoughtful Clinical Trials

Umberto Veronesi, Andrea Decensi

Affiliation of authors: European Institute of Oncology, Milan, Italy.

Correspondence to: Andrea Decensi, M.D., Division of Chemoprevention, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy (e-mail: andrea.decensi@ieo.it).

Ovarian cancer is a highly lethal disease and represents one of the leading causes of cancer death among women in Western countries. Since effective methods of screening and early diagnosis are lacking, prevention is being sought as one of the most promising ways to reduce mortality. While prophylactic oophorectomy is increasingly used for high-risk women, its short- and long-term morbidity is unknown. More important, most ovarian cancers are sporadic, and the widespread use of prophylactic oophorectomy in average-risk women is unimaginable. An epidemiologic study (1) has shown that oral contraceptive use is associated with reduced ovarian cancer risk among the general population as well as in BRCA1 heterozygotes. In women with a family history of breast cancer, however, oral contraceptive use is associated with additional risk of that disease (2). Thus, other agents are being studied that might replace or be combined with oral contraceptives for . . . [Full Text of this Article]

NOTES

REFERENCES


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Endocr Relat CancerHome page
S Zanardi, D Serrano, A Argusti, M Barile, M Puntoni, and A Decensi
Clinical trials with retinoids for breast cancer chemoprevention.
Endocr. Relat. Cancer, March 1, 2006; 13(1): 51 - 68.
[Abstract] [Full Text] [PDF]